Impact of polyethylene glycol loxenatide on cardiovascular outcomes in patients with type 2 diabetes: study protocol for a multicentre, randomised, double-blind, placebo-controlled trial (BALANCE-3)

INTRODUCTION: Recent cardiovascular outcomes trials have demonstrated that glucagon-like peptide 1 receptor agonist (GLP-1RA) decreases the incidence of major adverse cardiovascular events (MACEs) in individuals with type 2 diabetes mellitus (T2DM). Polyethylene glycol loxenatide (PEG-Loxe) is a onc...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Yun, Kuang, Jian, Li, Quanmin, Hong, Tianpei, Ji, Linong, Kong, Yuanyuan, Duan, Yale, Chen, Liming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Diabetes and Endocrinology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193081/
https://www.ncbi.nlm.nih.gov/pubmed/37192802
http://dx.doi.org/10.1136/bmjopen-2022-069080

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10193081/
https://www.ncbi.nlm.nih.gov/pubmed/37192802
http://dx.doi.org/10.1136/bmjopen-2022-069080

Ejemplares similares